Radiological characteristics predicting early poor drug response in patients with hemifacial spasm
Neurological Sciences · 2024
DOI: 10.1007/s10072-024-07389-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurological Sciences, 2024. Verfasst von Bo Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, The First People's Hospital of Foshan, Foshan, 528000, Guangdong Province, China. Hauptthemen laut MEDLINE: Hemifacial Spasm, Magnetic Resonance Imaging. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: the Foshan 14th Five-Year Plan Key Discipline Foundation.
Abstract (Originalsprache)
OBJECTIVES: Patients with hemifacial spasm (HFS) often resort to botulinum toxin injections or microvascular decompression surgery when medication exhibits limited effectiveness. This study aimed to identify MRI and demographic factors associated with poor drug response at an early stage in patients with HFS. METHODS: We retrospectively included patients with HFS who underwent pre-therapeutic MRI examination. The presence, location, severity, and the offending vessels of neurovascular compression were blindly evaluated using MRI. Drug responses and clinical data were obtained from the medical notes or phone follow-ups. Logistic regression analysis was performed to identify potential factors. RESULTS: A total of 116 patients were included, with an average age at the time of first examination of 50.4 years and a median duration of onset of 18 months. Forty-nine (42.2%) patients reported no symptom relief. Thirty-seven (31.9%) patients reported poor symptom relief. Twenty-two (19.0%) patients reported partial symptom relief. Eight (6.9%) patients achieved complete symptom relief. The factors that were statistically significant associated with poor drug responses were contact in the attach segment of the facial nerve and aged 70 and above, with an odds ratio of 7.772 (p = 0.002) and 0.160 (p = 0.028), respectively. CONCLUSIONS: This study revealed that mild compression in the attach segment of the facial nerve in pre-therapeutic MRI increases the risk of poor drug responses in patients with HFS, while patients aged 70 and above showed a decreased risk. These findings may assist clinician to choose optimal treatment at an early stage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, The First People's Hospital of Foshan, Foshan, 528000, Guangdong Province, China.
- Sun Yat-Sen University, Guangzhou, 510080, Guangdong Province, China.
- Institute of Translational Medicine, The First People's Hospital of Foshan, Foshan, 528000, Guangdong Province, China.
- Department of Functional Neurosurgery, The First People's Hospital of Foshan, Foshan, 528000, Guangdong Province, China.
- Department of Radiology, The First People's Hospital of Foshan, Foshan, 528000, Guangdong Province, China. 13760988108@163.com.
- Department of Radiology, The First People's Hospital of Foshan, Foshan, 528000, Guangdong Province, China. gmyong163@163.com.
Förderung
- the Foshan 14th Five-Year Plan Key Discipline Foundation
Zitieren
APA
Li, B., Huang, L., Luo, C., Jin, Y., Zhong, X., Wang, G., Xu, Z., Chen, J., Huang, S., Zhao, H., & Gao, M. (2024). Radiological characteristics predicting early poor drug response in patients with hemifacial spasm. Neurological Sciences. https://doi.org/10.1007/s10072-024-07389-9
Vancouver
Li B, Huang L, Luo C, Jin Y, Zhong X, Wang G, et al. Radiological characteristics predicting early poor drug response in patients with hemifacial spasm. Neurological Sciences. 2024. doi:10.1007/s10072-024-07389-9
BibTeX
@article{Li2024,
author = {Li, Bo and Huang, Linwen and Luo, Chun and Jin, Yabin and Zhong, Xuguang and Wang, Guofu and Xu, Zhifeng and Chen, Jingxian and Huang, Shengqiao and Zhao, Hai and Gao, Mingyong},
title = {Radiological characteristics predicting early poor drug response in patients with hemifacial spasm},
journal = {Neurological Sciences},
year = {2024},
doi = {10.1007/s10072-024-07389-9}
}
EUVIMED